A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Numakura, Tadahisa, Murakami, Koji, Tamada, Tsutomu, Yamaguchi, Chiaki, Inoue, Chihiro, Ohkouchi, Shinya, Tode, Naoki, Sano, Hirohito, Aizawa, Hiroyuki, Sato, Kei, Mitsune, Ayumi, Kurosawa, Hajime, Nakazawa, Toru, Sugiura, Hisatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646347/
https://www.ncbi.nlm.nih.gov/pubmed/35945009
http://dx.doi.org/10.2169/internalmedicine.0104-22
Descripción
Sumario:BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.

Ejemplares similares